MacroGenics, Inc. (MGNX)

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

Stock Picks From Seeking Alpha's September 2026 New Analysts

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead

Bank of America Corp DE Buys 564,094 Shares of MacroGenics, Inc. $MGNX

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of “Hold” by Brokerages

MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026